Skip to main content

Table 2 Clinical response after 1st line chemotherapy

From: Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

  ITT popuration (n = 90) KRAS wild type KRAS mutant
  p53 antibody p53 antibody p53 antibody
  Positive Negative Positive Negative Positive Negative
n (%) n = 36 (n = 54) (n = 11) (n = 31) (n = 13) (n = 13)
Complete Response 5(13.8) 2(3.7) 1(9) 1(3.2) 3(23) 0(0)
Partial Response (PR) 21(58.3) 41(74.0) 9(81.8) 25(80.6) 7(53.8) 9(69.2)
Stable Disease 5(5.5) 10(18.5) 1(9) 3(9.7) 3(23) 4(30.7)
Progressive Disease 2(8.3) 1(1.8) 0(0) 1(3.2) 0(0) 0(0)
Not Evaluable 3(8.3) 0(0) 0(0) 1(3.2) 0(0) 0(0)
PR in 26(72.2) 43(79.6) 10(91) 26(83.8) 10(76.9) 9(69.2)
Odds ratio (95 % CI) 1.1 (0.55–2.21) 0.92 (0.3–2.8) 0.9 (0.23–3.43)
P value 0.87 1 1